Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · regulatory

​FTC and seven states seek contempt ruling against Shkreli over pharma ban

13 October 2026 · By · Wire by Fusion42

Published

13 October 2026

Topic

regulatory

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at theguardian.com →

◆ Verified

Fusion42 · 13 October 2026 · Fusion42 review

The FTC and seven US states have filed a motion to hold Martin Shkreli in contempt for allegedly violating a lifetime ban on participation in the pharmaceutical industry by trading stocks and influencing pharmaceutical companies since his 2022 release.

This Wire brief sits within Fusion42's coverage of Biotech, and 8 sources have reported it between 13 Oct 2026 and 14 Oct 2026.

◆ ◆ The Wire takeaway

You face a clear enforcement risk if you engage in pharmaceutical stock trades under regulatory bans. This legal action shows regulators will pursue and penalise indirect pharma involvement immediately.

◆ Coverage

8 sources · first reported 13 Oct 2026 · latest 14 Oct 2026

◆ Topics

Biotechpharma-banftc-enforcementregulatory-compliancemarket-manipulationlegal-risk